NBD1 – Talk Bio

Sionna Therapeutics Aims for $150 Million IPO to Advance Cystic Fibrosis Treatments

3 months ago talkbio0Tagged Clinical Trials, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, IPO, Nasdaq, NBD1, Proteins, Sionna, Stabilizer - function

Sionna Therapeutics, IPO, cystic fibrosis, CFTR protein, NBD1 stabilizers, biotech, Nasdaq, clinical trials

Sionna Therapeutics Raises $191 Million in Upsized IPO for Cystic Fibrosis Drug Development

3 months ago talkbio0Tagged Clinical Trials, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, IPO, NBD1, Proteins, Sionna, Stabilizer - function

Sionna Therapeutics, cystic fibrosis, IPO, CFTR protein, NBD1 stabilizers, Vertex Pharmaceuticals, clinical trials

Sionna Secures $182M Series C Funding to Advance Novel Cystic Fibrosis Treatment Pipeline

1 year ago talkbio0Tagged Citation, Cystic, Cystic Cystic fibrosis, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, ICL4 inhibitor, NBD1, Sionna, Stabilizer - function

NBD1 stabilizers, ICL4 inhibitor, Cystic fibrosis, CFTR, NBD1, Cystic fibrosis, Cystic fibrosis, Sionna, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic fibrosis, Cystic Cystic fibrosis, Cystic fibrosis, Cystic Cystic, Cystic Cystic Cystic:, Search for the citation: